Chronic News and Research

RSS

Meta-analysis sheds light on effectiveness of chronic HBV treatments

A meta-analysis of treatments for chronic hepatitis B virus infection suggests that tenofovir disoproxil fumarate is the most effective option for patients positive and negative for hepatitis B e antigen, but the latter group may also benefit from entecavir treatment.

1 Jun 2015

ERC Advanced Grants awarded to seven ETH researchers

Seven ETH Zurich professors have applied successfully for an ERC Advanced Grant, which is worth about CHF 2.5 million. Two of the seven received the coveted award for the second time.

1 Jun 2015

Long sleep duration recommended for adults to sustain health and safety

In a new recommendation published in the June issue of SLEEP, the American Academy of Sleep Medicine (AASM) and Sleep Research Society (SRS) recommend that adults obtain seven or more hours of sleep per night to avoid the health risks of chronic inadequate sleep.

1 Jun 2015

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

The National Psoriasis Foundation received a second-year of funding from the Patient-Centered Outcomes Research Institute (PCORI) for its patient-driven, online research community.

1 Jun 2015

North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System®, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that the North American Spine Society (NASS) has issued their formal coverage recommendation for MIS SI joint fusion titled "Percutaneous Sacroiliac Joint Fusion, Defining Appropriate Coverage Positions."

1 Jun 2015

Simple one-hour therapy session cures 73% of people suffering from acute insomnia

A simple one-hour therapy session has helped to cure 73% of people suffering from acute insomnia, according to a new study from Northumbria University released today.

1 Jun 2015

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

For many people, bug bites and bee stings aren't a big deal beyond a small irritation. But for some, it could mean the start of a painful - possibly long-term or even deadly - experience.

1 Jun 2015

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Resverlogix Corp. today announced that new data on RVX-208 was presented at the ERA-EDTA Congress in London, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects with a History of CVD, and Chronic Kidney Disease (CKD); a Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ASSURE Clinical Trials."

1 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Statins reduce risk of death by 67% in CABG surgery

Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications.

1 Jun 2015

International Neuromodulation Society invites media to satellite-event news briefing before 12th World Congress

Representatives of the news media are invited to a satellite-event news briefing at 11 a.m. on June 6, 2015 before the International Neuromodulation Society 12th World Congress in Montreal.

1 Jun 2015

Connect.Parkinson national research study achieves enrollment target

The National Parkinson Foundation (NPF) announced today that the Connect.Parkinson national research study, comparing telemedicine care delivered to remote patients from a Parkinson's disease center of excellence to community-based care for Parkinson's disease, has achieved its enrollment target.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

The Lancet Diabetes & Endocrinology is pleased to announce that the following paper will be published to coincide with presentation at the 52nd ERA-EDTA Congress, taking place in London, UK, May 28 - 31, 2015.

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.

30 May 2015

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.

30 May 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill.

30 May 2015

Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Led by internationally-recognized cardiologists who are leaders in their field, the Peter Munk Cardiac Centre today announces the creation of an initiative to break ground in the cause, treatment and ongoing care of patients with an inherited, irregular heartbeat triggered by a rare cardiac structural condition.

30 May 2015

Chronic News and Research

Meta-analysis sheds light on effectiveness of chronic HBV treatments

ERC Advanced Grants awarded to seven ETH researchers

Long sleep duration recommended for adults to sustain health and safety

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

Simple one-hour therapy session cures 73% of people suffering from acute insomnia

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Statins reduce risk of death by 67% in CABG surgery

International Neuromodulation Society invites media to satellite-event news briefing before 12th World Congress

Connect.Parkinson national research study achieves enrollment target

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News